A competitive enzyme-linked immunosorbent assay for quantification of tetrastatin in body fluids and tumor extracts |
| |
Authors: | A. Dupont-Deshorgue J.B. Oudart B. Brassart G. Deslee J.M. Perotin M.D. Diebold J.C. Monboisse L. Ramont S. Brassart-Pasco |
| |
Affiliation: | 1. Centre National de la Recherche Scientifique (CNRS), Matrice Extracellulaire et Dynamique Cellulaire (MEDyC), 51095 Reims, France;2. Université de Reims Champagne–Ardenne, 51097 Reims, France;3. Laboratoire Central de Biochimie, Centre Hospitalier Universitaire (CHU) de Reims, 51092 Reims, France;4. Service des Maladies Respiratoires, Centre Hospitalier Universitaire (CHU) de Reims, 51092 Reims, France;5. Service d’Anatomie Pathologique, Centre Hospitalier Universitaire (CHU) de Reims, 51092 Reims, France |
| |
Abstract: | Basement membrane collagens or derived fragments are measured in biological fluids such as blood and urine of patients and appear to be useful for diagnosis, prognostication, or treatment monitoring as proposed for endostatin, a fragment of collagen XVIII, or tumstatin, a fragment of collagen IV. Tetrastatin, the NC1 alpha 4 collagen IV domain, was previously reported to inhibit tumor growth and angiogenesis. The aim of this study was to develop and validate a method to measure tetrastatin concentrations in human fluids. We developed a competitive enzyme-linked immunosorbent assay (ELISA). It allowed measuring tetrastatin levels in human serum, bronchial aspiration and bronchoalveolar lavage fluids, and lung tissue extracts. The tetrastatin level was significantly higher in tumor tissues than in healthy lung tissues. Tetrastatin competitive ELISA could be useful to quantify tetrastatin in tissues and biological fluids for the diagnosis or prognostication of diseases in which basement membrane metabolism may be altered, especially tumor progression. |
| |
Keywords: | Tetrastatin Collagen IV Competitive ELISA Pathologies |
本文献已被 ScienceDirect 等数据库收录! |
|